ArticleLife (Basel, Switzerland)2024
Immunohistochemical Evaluation of Basal and Luminal Markers in Bladder Cancer: A Study from a Single Institution.
Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AIF, CK5/6, and CK20 in Bladder Urothelial Carcinoma: A Cross-Sectional Immunohistochemical Study of Grade and Stage Associations.Journal of clinical medicine · 2026Article
- Emerging Molecular and Computational Biomarkers in Urothelial Carcinoma: Innovations in Diagnosis, Prognosis, and Therapeutic Response Prediction.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBladder cancer (BC) presents significant molecular diversity, which affects both prognosis and treatment results. Immunohistochemistry (IHC) facilitates the identification of molecular subtypes and their relationships with clinicopathological features.
methodsWe performed an IHC analysis on tissue samples from 107 BC patients, evaluating the expression of markers GATA3, CD44, CK5/6, and CK20. We applied two methods to classify the tumor samples into basal and luminal subtypes. The relationships between these marker expressions, molecular subtypes, clinicopathological characteristics, and TILs were explored.
resultsMost samples showed the expression of GATA3 and CD44, with notable correlations found between CD44 and CK5/6 as well as GATA3 and CK20. CD44 and CD20 expression were linked to a poorer prognosis. Additionally, the luminal and basal subtypes had distinct TIL patterns, which influenced overall survival. A poor prognosis was associated with the basal subtype with low TIL infiltration and the luminal subtype with high TIL infiltration.
conclusionsOur study clarifies the molecular characteristics of BC, underlining the prognostic importance of CD44 expression and the role of TILs in influencing subtype-specific outcomes. IHC proves valuable in subtype identification and supports personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.